Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Most descriptive claims about mechanism and GI effects align with provided label excerpts, and several specific label-based points (adjunct for glycemic control in adults, postprandial glucose use, dextrose vs sucrose, GI side effects, contraindication-related glucose control risk with sulfonylurea/insulin) are consistent. However, multiple claims are not supported by the provided excerpts as stated (e.g., class-level statements about “reducing spikes,” hypoglycemia not causing by class vs Precose alone, and specific labeling of contraindications). Several safety-related items are only partially supported.
Category Scores
Accurate Statements
Precose is the brand name for acarbose.
Implied by the provided label excerpts stating PRECOSE is the drug product and active ingredient is acarbose (and labeling context).
Acarbose is an oral medicine used to treat type 2 diabetes.
INDICATIONS AND USAGE: adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Acarbose belongs to the drug class alpha-glucosidase inhibitors.
WARNINGS/ADVERSE REACTIONS excerpts reference alpha-glucosidase inhibitors, including Precose (Pneumatosis cystoides intestinalis section).
Alpha-glucosidase inhibitors (including acarbose) reduce post-meal blood sugar spikes.
12 CLINICAL PHARMACOLOGY: delayed glucose absorption and lowering of postprandial hyperglycemia.
Common side effects of this class are typically gastrointestinal.
6 ADVERSE REACTIONS: Gastrointestinal symptoms are the most common reactions.
Common gastrointestinal side effects include gas, bloating, and diarrhea.
6 ADVERSE REACTIONS: abdominal pain, diarrhea, flatulence (gas). Bloating is not explicitly listed in provided excerpts.
When taking acarbose, if hypoglycemia occurs, sugar may not work as quickly because acarbose slows carbohydrate digestion.
WARNINGS AND PRECAUTIONS (Hypoglycemia): sucrose is unsuitable for rapid correction; oral glucose (dextrose) should be used instead.
Hypoglycemia should be treated with glucose (dextrose), not just table sugar, for alpha-glucosidase inhibitors.
WARNINGS AND PRECAUTIONS (Hypoglycemia): Oral glucose (dextrose) should be used instead of sucrose.
Unsupported Statements
Alpha-glucosidase inhibitors (including acarbose) work in the gut to slow carbohydrate digestion.
Mechanism described as enzyme inhibition leading to delayed glucose absorption and lowering of postprandial hyperglycemia; provided excerpts do not explicitly use the phrase “slow carbohydrate digestion.”
Alpha-glucosidase inhibitors act locally in the digestive tract by blocking enzymes that break down complex carbohydrates into absorbable sugars.
Label excerpt describes inhibition of alpha-amylase and intestinal alpha-glucosidase hydrolase enzymes leading to delayed glucose absorption; it does not explicitly state “complex carbohydrates into absorbable sugars” or “act locally” wording.
Blocking those enzymes blunts the rise in glucose after eating.
Label supports delayed glucose absorption and lowering of postprandial hyperglycemia, but does not explicitly state “blunts the rise in glucose.”
Precose is used in adults with type 2 diabetes to help control blood sugar.
Generally consistent with indication, but the provided excerpt specifies “adjunct to diet and exercise” and “improve glycemic control”; the claim omits adjunct requirement and exact wording (minor omission).
Precose helps control blood sugar particularly by reducing increases that occur after meals.
Label excerpt supports lowering of postprandial hyperglycemia; however the claim’s emphasis “particularly” is not explicitly stated.
Common gastrointestinal side effects include gas, bloating, and diarrhea.
“Gas” and diarrhea are supported (flatulence; diarrhea). “Bloating” is not explicitly listed in the provided adverse reaction incidences.
Acarbose is an oral medicine used to treat type 2 diabetes.
Oral route is supported by tablet dosage form provided in the prompt context, but the label excerpt itself provided does not explicitly say “oral”.
Contradictions
Low
AI Statement
When taking acarbose, if hypoglycemia occurs, sugar may not work as quickly because acarbose slows carbohydrate digestion.
Label Reference
WARNINGS AND PRECAUTIONS (Hypoglycemia): sucrose is unsuitable for rapid correction because hydrolysis is inhibited; dextrose should be used.
Important Omissions
Dose titration details and maximum recommended dose; start with first bite of each main meal; no fixed dosage regimen; individualized dosing while not exceeding 100 mg t.i.d.
Importance:
Moderate
Contraindication specifics (e.g., diabetic ketoacidosis, cirrhosis, inflammatory bowel disease, colonic ulceration, partial intestinal obstruction, predisposition to intestinal obstruction, chronic intestinal diseases with marked disorders of digestion/absorption). None of the AI claims mentioned contraindications.
Importance:
Moderate
Laboratory monitoring recommendations (serum transaminases every 3 months during first year; periodically thereafter) and management if elevations observed.
Importance:
Moderate
Drug interaction details beyond the hypoglycemia sugar correction concept (e.g., intestinal adsorbents and carbohydrate-splitting digestive enzyme preparations should not be taken concomitantly).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several safety-critical label elements (contraindications, monitoring of transaminases, and interaction restrictions) were not addressed. Some mechanism/side-effect wording is imprecise, though hypoglycemia treatment with dextrose vs sucrose is supported.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Aligned
Primary Issue
Material label omissions: contraindications, dosing/titration and max dose, and monitoring (transaminases). Several mechanism and symptom statements are not precisely supported in the provided excerpts as phrased.
Suggested Improvement
Add label-supported contraindications and dose administration/titration details; include recommended transaminase monitoring; rephrase mechanism/side-effect claims to match the label wording (e.g., delayed glucose absorption; flatulence/diarrhea; avoid adding “bloating” unless explicitly supported).